Neuren Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Neuren Pharmaceuticals has a total shareholder equity of A$323.3M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$331.3M and A$8.0M respectively. Neuren Pharmaceuticals's EBIT is A$184.1M making its interest coverage ratio -16. It has cash and short-term investments of A$299.5M.
Key information
0%
Debt to equity ratio
AU$0
Debt
| Interest coverage ratio | -16x |
| Cash | AU$299.54m |
| Equity | AU$323.27m |
| Total liabilities | AU$7.98m |
| Total assets | AU$331.25m |
Recent financial health updates
Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business
Jan 07
We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth
Sep 06Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth
May 31We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn
Feb 03Recent updates
Investors Shouldn't Be Too Comfortable With Neuren Pharmaceuticals' (ASX:NEU) Earnings
Sep 02Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Is Well Worth Watching
Aug 27Neuren Pharmaceuticals Limited (ASX:NEU) Shares Fly 26% But Investors Aren't Buying For Growth
Jul 22Neuren Pharmaceuticals Limited (ASX:NEU) Shares Fly 30% But Investors Aren't Buying For Growth
May 16
DAYBUE And NNZ-2591 Will Expand Markets While Facing Regulatory Risks
Strong financial position and partnerships reduce the need for capital raising, protecting margins and earnings.Investors Don't See Light At End Of Neuren Pharmaceuticals Limited's (ASX:NEU) Tunnel
Apr 01A Look At The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)
Feb 06Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Is Well Worth Watching
Jan 15New Forecasts: Here's What Analysts Think The Future Holds For Neuren Pharmaceuticals Limited (ASX:NEU)
Nov 11Neuren Pharmaceuticals Limited's (ASX:NEU) Shares Climb 26% But Its Business Is Yet to Catch Up
Nov 08Calculating The Intrinsic Value Of Neuren Pharmaceuticals Limited (ASX:NEU)
Oct 24Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models
Aug 29Pinning Down Neuren Pharmaceuticals Limited's (ASX:NEU) P/S Is Difficult Right Now
Aug 14Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today
May 31Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely
May 03An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued
Apr 01Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically
Mar 05Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors
Mar 02Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors
Dec 18Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues
Sep 02Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)
Aug 31This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year
Mar 03Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business
Jan 07We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth
Sep 06Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth
May 31We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn
Feb 03Financial Position Analysis
Short Term Liabilities: NEU's short term assets (A$320.2M) exceed its short term liabilities (A$7.9M).
Long Term Liabilities: NEU's short term assets (A$320.2M) exceed its long term liabilities (A$55.0K).
Debt to Equity History and Analysis
Debt Level: NEU is debt free.
Reducing Debt: NEU has not had any debt for past 5 years.
Debt Coverage: NEU has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: NEU has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/01 09:44 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Neuren Pharmaceuticals Limited is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Melissa Benson | Barrenjoey Markets Pty Limited |
| Thomas Wakim | Bell Potter |
| Elyse Shapiro | Canaccord Genuity |